Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
Insulin glargine plus metformin and glimepiride improves glycemic control in type 2 diabetes.
Last updated August 18, 2026
Key finding
HbA1C levels improved from (mean ± SD) 8.5±0.9% to 7.7±0.8%.
Insulin glargine added to metformin and glimepiride in adults with type 2 diabetes.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
Insulin glargine added to metformin and glimepiride in adults with type 2 diabetes.
Clinical relevance
This study evaluated Insulin glargine added to metformin and glimepiride in adults with type 2 diabetes.
Keep in mind
Limitations were not clearly described in the extracted text.
Published in
Journal Reference
Publication details and source links for this paper.
Cheol-Young P, Jun GK, Suk C, et al. Comparison of Insulin Glargine with Oral Anti-Diabetic Drug Combinations in Type 2 Diabetes. PLoS ONE. 2014;9(3):e87799. doi:10.1371/journal.pone.0087799
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Glimepiride, Metformin, Metformin + glimepiride and Basal insulin dose, Body weight, Fasting Plasma Glucose (FPG), and 2 more.
This study contributes evidence to
Primary intervention
Glimepiride
Primary outcomes
- Basal insulin dose
- Body weight
- Fasting Plasma Glucose (FPG)
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
15
Evidence pairs
15
Relationships
6
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
6
Related topics
15
Evidence pairs
1917
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 15 evidence relationships
- Includes primary outcome data
- Linked to 6 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
Sulfonylureas and HbA1c
Related evidence
Evidence relationship
Metformin Therapies and Fasting Glucose
Save evidence
Evidence relationship
Metformin Therapies and HbA1c
Save evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 38
- Slightly Negative
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 2 studies
Add to Evidence TrackerFasting Plasma Glucose (FPG)
Glimepiride → Fasting Plasma Glucose (FPG)
Glimepiride → Fasting Plasma Glucose (FPG)
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 84
- Strong
- ImpactScore™
- 80
- Positive
- ConsistencyScore™
- 80
- consistent
Supporting studies: Based on 5 studies
Add to Evidence TrackerSymptomatic hypoglycemia
Glimepiride → Symptomatic hypoglycemia
Glimepiride → Symptomatic hypoglycemia
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 83
- Strong
- ImpactScore™
- 70
- Positive
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 5 studies
Add to Evidence TrackerFasting Plasma Glucose (FPG)
Metformin → Fasting Plasma Glucose (FPG)
Metformin → Fasting Plasma Glucose (FPG)
Evidence Intelligence™
- EvidenceScore™
- 84
- Strong
- ImpactScore™
- 79
- Positive
- ConsistencyScore™
- 71
- generally_consistent
Supporting studies: Based on 7 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 85
- Strong
- ImpactScore™
- 88
- Very Positive
- ConsistencyScore™
- 73
- generally_consistent
Supporting studies: Based on 12 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerBasal insulin dose
Metformin + glimepiride → Basal insulin dose
Metformin + glimepiride → Basal insulin dose
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 75
- Positive
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 2 studies
Add to Evidence TrackerFasting Plasma Glucose (FPG)
Metformin + glimepiride → Fasting Plasma Glucose (FPG)
Metformin + glimepiride → Fasting Plasma Glucose (FPG)
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 77
- Strong
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 3 studies
Add to Evidence TrackerSymptomatic hypoglycemia
Metformin + glimepiride → Symptomatic hypoglycemia
Metformin + glimepiride → Symptomatic hypoglycemia
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Metformin Therapies and HbA1c, Sulfonylureas and HbA1c.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Metformin Therapies → HbA1c
Medications
Evidence Intelligence™
- EvidenceScore™
- 85
- Strong
- ImpactScore™
- 88
- Very Positive
- ConsistencyScore™
- 73
- generally_consistent
Supporting studies: Based on 12 studies
View evidenceMedications
Sulfonylureas → HbA1c
Medications
Evidence Intelligence™
- EvidenceScore™
- 84
- Strong
- ImpactScore™
- 80
- Positive
- ConsistencyScore™
- 80
- consistent
Supporting studies: Based on 5 studies
View evidenceMedications
Metformin Therapies → Body Weight
Medications
Evidence Intelligence™
- EvidenceScore™
- 83
- Strong
- ImpactScore™
- 70
- Positive
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 5 studies
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
HbA1c Evidence Hub
All studies measuring HbA1c
12 studies
outcome_hubMeasures HbA1c as a key outcome.
Metformin Therapies Evidence Hub
All studies on Metformin Therapies
12 studies
intervention_hubContributes to Metformin Therapies evidence base.
Body Weight Evidence Hub
All studies measuring Body Weight
5 studies
outcome_hubMeasures Body Weight as a key outcome.
Sulfonylureas Evidence Hub
All studies on Sulfonylureas
5 studies
intervention_hubContributes to Sulfonylureas evidence base.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Metformin and HbA1c
Intervention: MetforminOutcome: HbA1c
12 results
All studies on Glimepiride and HbA1c
Intervention: GlimepirideOutcome: HbA1c
5 results
All studies on Metformin
Intervention: Metformin
12 results
All studies on Glimepiride
Intervention: Glimepiride
5 results
All studies measuring HbA1c
Outcome: HbA1c
12 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Do Sulfonylureas lower HbA1c?
Strong Evidence
Sulfonylureas may lower HbA1c.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 84.2 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 9 supporting studies with generally consistent results and a positive effect signal.
Do Metformin Therapies improve fasting glucose?
Strong Evidence
Metformin Therapies may improve fasting glucose.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Evidence caveat: The available evidence reports mixed findings.
Ranked evidence signals
- 1
Fasting Plasma Glucose (FPG)
EvidenceScore™ Strong | EvidenceScore™ 83.9 | moderate positive | ConsistencyScore™ Generally Consistent | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Do Metformin Therapies lower HbA1c?
Strong Evidence
Metformin Therapies appear to lower HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 85.3 | strong positive | ConsistencyScore™ Generally Consistent | 1 study
Why this answer: This answer is based on 14 supporting studies with consistent results and a positive effect signal.
Do Sulfonylureas affect body weight?
Strong Evidence
Sulfonylureas may affect body weight.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | weak negative | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is based on 5 supporting studies with generally consistent results and a positive effect signal.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Vildagliptin and Metformin Improve Glycemic Control in Type 2 DiabetesDietary Modulation of Gut Microbiota in PrediabetesExercise Improves Serum Albumin Levels in Women with Type 2 DiabetesHRS-7535 improves glycemic control in adults with type 2 diabetesPharmacotherapy may achieve diabetes remission
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.